<DOC>
	<DOCNO>NCT01084148</DOCNO>
	<brief_summary>Primary objective : To demonstrate long-term efficacy ( response treatment initial therapy , time relapse without treatment , durability lesional recurrence maintenance therapy ) V0034 CR 01B cream uraemic xerosis real-life setting . Secondary objective : 1 . To assess local tolerance V0034 CR 01B long-term use 2 . To assess patient benefit acceptability V0034 CR 01B</brief_summary>
	<brief_title>Long-term Efficacy Safety V0034 CR 01B Cream Patients With Moderate-to-severe Uremic Xerosis</brief_title>
	<detailed_description />
	<criteria>1 . Patients sexes , least 18 year age 2 . Women childbearing potential reliable contraceptive method 3 . Patients undergoing maintenance renal dialysis ( MRD ) , i.e . either haemodialysis peritoneal dialysis , due chronic renal failure 4 . Patients whose xerosis relate renal insufficiency status ( uraemic xerosis ) 5 . Patients suffer xerosis severity score least two , least one five test area ( right low leg , leave low leg , forearm arteriovenous shunt , chest , dorsum neck ) 1 . Patients 18 year age 2 . Women childbearing potential positive pregnancy test baseline 3 . Patients undergoing renal dialysis another reason chronic renal insufficiency 4 . Patients whose xerosis due another reason MRD status 5 . Patients suffer mild xerosis ( i.e . score less two xerotic test area ) 6 . Patients known history allergy one ingredient contain test product 7 . Patients intercurrent condition may interfere good conduct study parameter study 8 . Patients treat emollient/moisturising topical preparation within seven day prior study entry 9 . Patients participate study within three month prior study entry 10 . Patients affiliate health insurance 11 . Patients able willing follow study instruction</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>